Key statistics
On Tuesday, Sagimet Biosciences Inc (SGMT:NMQ) closed at 5.62, 224.86% above the 52 week low of 1.73 set on Apr 07, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 5.57 |
|---|---|
| High | 5.68 |
| Low | 5.34 |
| Bid | 5.45 |
| Offer | 5.70 |
| Previous close | 5.72 |
| Average volume | 414.29k |
|---|---|
| Shares outstanding | 32.52m |
| Free float | 28.96m |
| P/E (TTM) | -- |
| Market cap | 186.02m USD |
| EPS (TTM) | -1.79 USD |
Data delayed at least 15 minutes, as of Mar 03 2026 21:00 GMT.
More ▼
- Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences
- Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences
- Sagimet Announces Positive 52-Week Data from License Partner Ascletis’ Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne
- Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference
- Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination
- Sagimet Biosciences and TAPI Announce Global License Agreement for Innovative Forms of Resmetirom API for Sagimet’s Fixed Dose Combination Program
- Sagimet’s License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China’s National Medical Products Administration
- Sagimet Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare Conference
- Sagimet Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
More ▼
